Figure 2.

Adjusted predicted triglyceride levels over time after TDF-to-TAF switch, estimated from a linear regression model with linear splines, maintained other ARVs (n = 4328).^{a a}Estimated from a linear regression model fit with generalized estimated equations, with linear splines on time (knots at 3, 9, 16 months); reference covariate pattern: male aged 45, on TDF for 24 months and with a triglyceride value of 163 mg/dL at the last lipid panel before switch, a viral load <50 copies/mL throughout follow-up, and no hormone, statin, nonstatin lipid-lowering agent, pharmaco-enhancer, or PI use at any point during follow-up. Abbreviations: LDL, low-density lipoprotein; PI, protease inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; TG, triglycerides.